drugset / Trial / NCT05050630
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
Phase 2
Unknown
73 enrolled
Affiliated Hospital to Academy of Military Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collabPeking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year overall survival (OS) were the secondary endpoint. To evaluate the efficacy and safety of TR2-ICE sequential Tirelarizin, lenalidomide alone, or both maintenance therapy in the rescue of patients with relapsed and refractory diffuse large B or high-grade B-cell lymphoma.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2022-07-30
- Completion
- 2023-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 5 g | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | — |